Harper Forbes
Overview
Explore the profile of Harper Forbes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
8
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jain P, Forbes H, Gorneau J, Esposito L
Zookeys
. 2023 Dec;
1185:199-239.
PMID: 38074909
Herein a new species of Werner, 1934 is described from alkali-sink habitats in the San Joaquin Desert of central California, It can be differentiated from other by a combination of...
2.
Jain P, Forbes H, Esposito L
Zookeys
. 2023 Feb;
1117:139-188.
PMID: 36761381
Herein we describe two new species of (Werner 1934) from California: from the Soda Lake playa at the center of the Carrizo Plain in San Luis Obispo county and from...
3.
Zhang W, Mathisen M, Goodman G, Forbes H, Song Y, Bertran E, et al.
Clin Pharmacol Drug Dev
. 2020 Jul;
10(1):39-45.
PMID: 32602215
The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study. Patients with BRAF mutation-positive metastatic malignancies...
4.
Zhang W, McIntyre C, Riehl T, Forbes H, Bertran E, Choi H, et al.
Clin Pharmacol Drug Dev
. 2020 Apr;
9(5):651-658.
PMID: 32311241
This phase 1 open-label, multicenter, 3-period, fixed-sequence study evaluated the effect of multiple doses of vemurafenib on the pharmacokinetics of 1 dose of tizanidine, a probe CYP1A2 substrate, in patients...
5.
Zhang W, Colburn D, Simmons B, Papai Z, Bertran E, Schadt S, et al.
Clin Pharmacol Drug Dev
. 2020 Feb;
9(4):496-504.
PMID: 32083398
Vemurafenib is a BRAF kinase inhibitor indicated for the treatment of patients with BRAF mutation-positive unresectable or metastatic melanoma and Erdheim-Chester disease. This phase 1, open-label, single-arm study was designed...
6.
Zhang W, McIntyre C, Forbes H, Gaafar R, Kohail H, Beck J, et al.
Clin Pharmacol Drug Dev
. 2018 Dec;
8(6):837-843.
PMID: 30570831
Vemurafenib prolongs survival in patients with BRAF -mutated advanced melanoma. In vitro studies show cytochrome P450 (CYP) 3A4 is involved in vemurafenib metabolism, but the effect of strong inducers or...
7.
Zhang W, McIntyre C, Kuhn M, Forbes H, Kim T, Lee J, et al.
J Clin Pharmacol
. 2018 Apr;
58(8):1067-1073.
PMID: 29645280
The primary objective of this phase 1, open-label, multicenter, 3-period, fixed-sequence study was to evaluate the effect of multiple doses of vemurafenib on the pharmacokinetics of a single dose of...